USA releases new IPEC plan of action to defend and enforce intellectual property, including for Pharma

28 June 2010

Last week, Victoria Espinel, the US Barack Obama Administration's Intellectual Property Enforcement Coordinator (IPEC), released the "Joint Strategic Plan on Intellectual Property Enforcement" that Congress ordered when it created the IPEC position. The plan ' the results of a month-long public process - lays out 33 "enforcement action items" grouped in six categories.

Overall, the plan is chiefly about what the federal government can do to better coordinate its own enforcement efforts over a whole host of areas, such as blocking trafficking in counterfeit medicines, rooting out infringing software among federal contractors, and improving communication between federal and state enforcement agencies.

US Trade Representative Ron Kirk joined Vice President Biden, members of the President's cabinet and Ms Espinel to announce the Joint Strategic Plan on Intellectual Property Enforcement. The Obama Administration, including USTR, highlighting the need to safeguard US intellectual property because such protection is fundamental to safeguard American jobs, sustain American exports and strengthen the American economy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical